10x Genomics Inc (NASDAQ:TXG) shares, rose in value on Wednesday, July 09, with the stock price down by -1.22% to the previous day’s close as strong demand from buyers drove the stock to $12.1.
Actively observing the price movement in the last trading, the stock closed the session at $12.25, falling within a range of $11.89 and $12.66. The value of beta (5-year monthly) was 1.981. Referring to stock’s 52-week performance, its high was $24.76, and the low was $6.78. On the whole, TXG has fluctuated by 28.45% over the past month.
With the market capitalization of 10x Genomics Inc currently standing at about $1.51 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TXG’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of TXG currently trading nearly 5.97% and 22.18% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.16, while the 7-day volatility ratio is showing 6.80% which for the 30-day chart, stands at 6.36%. Furthermore, 10x Genomics Inc (TXG)’s beta value is 2.01.
A comparison of 10x Genomics Inc (TXG) with its peers suggests the former has fared considerably weaker in the market. TXG showed an intraday change of -1.22% in last session, and over the past year, it shrunk by -15.74%%.
Data on historical trading for 10x Genomics Inc (NASDAQ:TXG) indicates that the trading volumes over the past 10 days have averaged 5.18 and over the past 3 months, they’ve averaged 4.12 million. According to company’s latest data on outstanding shares, there are 109.08 million shares outstanding.
Nearly 15.39% of 10x Genomics Inc’s shares belong to company insiders and institutional investors own 90.18% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 13.43 million shares as on 2025-06-13, resulting in a short ratio of 3.59. According to the data, the short interest in 10x Genomics Inc (TXG) stood at 1809.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 14.88 million. The stock has fallen by -35.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TXG stock heading into the next quarter.
